Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Hormone. Karolinska Institutet and University Hospital, Stockholm, Sweden

Survival: 37.8 months
Toxicity Grade: 5
Treatments: Hormone
Country: Sweden
City/State/Province: Stockholm
Hospital: Karolinska Institutet and University Hospital
Journal: Link
Date: 6/2012

This phase 3 study involved women with receptor-positive postmenopausal breast cancer who were divided into two separate treatment groups. Group A consisted of 258 patients with a median age of 65 years. Group B had 256 patients with a median age of 63 years.

Patients in group A were treated with two hormone therapy agents, fulvestrant and anastrozole. Fulvestrant inhibits a hormone receptor on the cell and prevents it from giving growth signals to the cell. Anastrozole is an “aromatase inhibitor” that inhibits the production of the growth-stimulating estrogen hormone.

Patients in group B were treated with the hormone therapy anastrozole alone.

There were 11 treatment-related deaths in group A. Causes included heart attack, pneumonia, kidney failure, and infection. Gastrointestinal disorders and hot flashes were also reported.

There were 5 treatment-related deaths in group B. Causes included heart attack and pneumonia. Gastrointestinal disorders and hot flashes were also reported.

The median overall survival rates for groups A and B were 37.8 and 38.2 months, respectively

This study was supported by AstraZeneca, makers of Arimidex (brand name for anastrozole) and Faslodex (brand name for fulvestrant).

Correspondence: Dr. Jonas Bergh; email:

E-mail to a Friend Email Physician More Information